Factor VIII auto- and alloantibodies neutralise porcine factor VIII to a lesser extent than factor VIII of human origin. The reduced reactivity of the porcine molecule, predominantly due to sequence variation in the A2 and C2 domains, has been the rationale for using porcine factor VIII to secure haemostasis for patients with factor VIII inhibitors. Porcine factor VIII has been shown to provide effective haemostatic control particularly for patients with intermediate inhibitor titres with limited porcine cross-reactivity. Small studies have indicated porcine factor VIII can be associated with desensitisation of some factor VIII inhibitor patients. Porcine factor VIII has been shown to produce mild platelet agglutination, an effect that may enhance its efficacy. Adverse reactions are dose-related and do not preclude safe and effective long-term home use for the subgroup of inhibitor patients with modest or absent anamnestic response. Efforts to secure source plasma free of viral markers, particularly porcine parvovirus, have limited the supply of this therapeutic product.
© 2002 S. Karger AG, Basel
- Porcine FVIII
- Hybrid FVIII
- Kernoff PB, Thomas ND, Lilley PA, Matthews KB, Goldman E, Tuddenham EG: Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. Blood 1984;663:31–41.
- Brettler DB, Forsberg AD, Levine PH, Aledort LM, Hilgartner MW, Kasper CK, Lusher JM, McMillan C, Roberts H: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med 1989;149:1381–1385.
- Hay CR, Lozier JN, Lee CA, Laffan M, Tradati F, Santagostino E, Ciavarella N, Schiavoni M, Fukui H, Yoshioka A, Tietel J, Mannucci PM, Kasper CK: Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia A and inhibitors: The results of an international survey. Thromb Haemost 1996;75:25–29.
- Hay CR, Laurian Y, Verroust F, Preston FE, Kernoff PB: Induction of immune tolerance in patients with hemophilia A and inhibitors treated with porcine VIIIC by home therapy. Blood 1990;76:882–886.
- Vyas P, Pasi KJ, Lee CA: Successful long-term treatment with porcine factor VIII of a patient with haemophilia A and an inhibitor to factor VIII. Haemophilia 1996;2:240–243.
- Morrison AE, Ludlam CA, Kessler C: Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993;81:1513–1520.
- Hermans C, Owens D, Longo G, Morfini M, Lee C.A: Single-dose pharmacokinetics of porcine factor VIII (Hyate C). Thromb Haemost 2002;87:352–353.
- Lollar P, Parker ET, Curtis JE, Helgerson SL, Hoyer LW, Scott ME, Scandella D: Inhibition of human factor VIIIa by anti-A2 subunit antibodies. J Clin Invest 1994;93:2497–2504.
- Arai, M, Scandella D, Hoyer LW: Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989;83:1978–1984.
- Lollar P: Analysis of factor VIII inhibitors using hybrid human/porcine factor VIII. Thromb Haemost 1997;78:647–651.
- Hay CRM, DiMichele D, Rivard G, Rubinger M, Gribble J: Workshop III – porcine factor VIII – continuous infusion, immune tolerance induction and prophylaxis. Haemophilia 1997;3(suppl 3):24–30.
Prof. Christine Lee, Centre Director
Royal Free Hospital, Pond Street
London, NW3 2QG (UK)
Tel. +44 207 7830 2238, Fax +44 207 7830 2468, E-Mail email@example.com
Number of Print Pages : 4
Number of Figures : 2, Number of Tables : 0, Number of References : 11
Pathophysiology of Haemostasis and Thrombosis
Official Journal of the ‘Mediterranean League against Thromboembolic Diseases’
Vol. 32, No. Suppl. 1, Year 2002 (Cover Date: Released April 2002)
Journal Editor: H.C. Hemker, Maastricht
ISSN: 1424–8832 (print), 1424–8840 (Online)
For additional information: http://www.karger.com/journals/pht
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.